SHENZEN, China, May 24 /PRNewswire-FirstCall/ - Hard to Treat
Diseases, Inc. (HTDS; http://www.htdsmedical.com) and Shenzhen
Mellow Hope (www.mellowhope.com) is providing the following update
to its shareholders and followers regarding business expectations
for 2010
Mr.Terry Yuan CEO of HTDS has met with its IR firm Mina Mar
Group here in China to address
many concerns that shareholders have expressed. It was decided that
the best way to address these concerns was to hear (audio
recording) directly from the top brass. The company is pleased to
provide raw, uncut, non scripted address by Mr Terry Yuan CEO of
HTDS. The audio can be listened at www.minamargroup.com/htds The
company reminds the audio listeners that English is a second
language for Mr.Yuan and that he made the address based on FAQ
questions posed by HTDS shareholders.
Here are some snippets from the audio recording. The company
expects strong revenue increases in the upcoming Quarters. The
company management developments on the global vaccine market
(listed below), Mellow Hope expects to top the 2009 profits and
further expand on the global vaccine market in 2010 and 2011. The
company expects the income from MEVAC-ACYW (Meningococcal
Polysaccharide Vaccine) in Pakistan and Indonesia to generate $2 million USD in 2010.
Regarding Mellow Hope's MEVAC-A vaccine, the company expects the
existing market in India to
increase at the rate of 20-40%. In this light, the company expects
to increase its MEVAC-A sales in India by 100%. Besides India, the company received Clinical Trial
Permit for the MEVAC-A vaccine in Russian
Federation, and expects to obtain registration by the end of
2010, opening a large market for Mellow Hope.
Mellow Hope expects to finalize the approval of its Nutriprotein
Product (Cerebroprotein Hydrolysate for Injection) in India in Jun/July
2010. The company will start marketing its Nutriprotein
product immediately. Mellow Hope believes the company is the only
one marketing this type of product in India, with a potential to generate
$10 million USD in sales (the company
expects to sell 2-3 million doses annually - press release
March 1, 2010).
Besides these developments, the company continues to cooperate
with health ministries in Asia,
Europe and Latin America to gain approval for several
other vaccines in 2010 and in 2011.
With all the current and planed developments, Mellow Hope
management is confident that the shareholders will see stronger
results in 2010 and in 2011, as the company will gain even larger
market share on the global vaccine market. In other news and
events,the company has filed all documents with FINRA for the HIRU
shares distribution and expects to hear back from FINRA shortly.
The company has also recently started subscribing to Pink Sheets
filing service and will shortly update the Adequate Disclosure
documents with a legal opinion from a USA legal counsel in aid of upgrading its Pink
Sheets ranking.
The company reminds its shareholders and followers to monitor
PinkSheets.com Filing section and also our IR company web site
section "PRESS RELEASES AND FILINGS" TAB
http://www.minamargroup.net/ for non newsworthy corporate
updates.
For any matters relating to retail investor queries or to send
the company or its IR a message please click on the "INVESTOR
SUPPORT" TAB, or the direct link
http://www.minamargroup.net/helpdesk. In this regard, Mina Mar
Group works diligently to answer and address all the pressing
issues regarding its clients to the shareholders' satisfaction. MMG
is in constant contact with the companies, addressing, obtaining
and processing all inquiries. MMG is often one of the advisors or
IR companies utilized by the issuer. Depending on the location of
the issuer and management's availability, it may take up to several
days to address any pressing issues. In a normal course of business
and a pending transaction, the issuer may opt to remain silent in
order not to lose advantage to a competitor. MMG is mindful that
sometimes shareholders want answers immediately, which for the
above reasons cannot be fulfilled on a timely basis.
Don't be a victim. Report a stock basher to authorities. The
company is mindful that short sellers, the company's competitors
and stock bashers stalk small cap Pink Sheets listed companies with
hidden agendas. Visit http://www.stockbasher.com/ and find out what
criminal and civil actions the US authorities are taking against
web sites like investorshub.com and other posters, and the remedies
available to you as an individual investor. MMG encourages the
readers to visit this investorshub.com blog and similar "investors"
web sites with an open mind. Discover for yourself why and how
USA based small businesses and the
backbone of the economy suffer. Stay informed and do not allow
entrepreneurs' dreams, innovations, and their access to capital to
be thwarted as "scalpers" and day traders vigorously day in and day
out try to exploit and extinguish US innovation and progress for
quick profits.
Filings for this event are currently being reviewed and will be
filed with Pink Sheets and Client Support section in due course. To
be included in company's email database for press releases,
industry updates, and non-weekly activity in the company that may
or may not be news released, please subscribe or opt in mailer at
http://www.minamargroup.com/updates.
Safe Harbor Statement
Information in this news release may contain statements about
future expectations, plans, prospects or performance of Hard to
Treat Diseases, Inc. that constitute forward-looking statements for
purposes of the Safe Harbor Provisions under the Private Securities
Litigation Reform Act of 1995. The words or phrases "can be",
"expects", "may affect", "believed", "estimate", "project" and
similar words and phrases are intended to identify such
forward-looking statements. Hard to Treat Diseases, Inc. cautions
you that any forward-looking information provided by or on behalf
of Hard to Treat Diseases, Inc. is not a guarantee of future
performance. None of the information in this press release
constitutes or is intended as an offer to sell securities or
investment advice of any kind. Hard to Treat Diseases, Inc.'s
actual results may differ materially from those anticipated in such
forward-looking statements as a result of various important
factors, some of which are beyond Hard to Treat Diseases, Inc.'s
control. In addition to those discussed in Hard to Treat Diseases,
Inc.'s press releases, public filings, and statements by Hard to
Treat Diseases, Inc.'s management, including, but not limited to,
Hard to Treat Diseases, Inc.'s estimate of the sufficiency of its
existing capital resources, Hard to Treat Diseases, Inc.'s ability
to raise additional capital to fund future operations, Hard to
Treat Diseases, Inc.'s ability to repay its existing indebtedness,
the uncertainties involved in estimating market opportunities, and
in identifying contracts which match Hard to Treat Diseases, Inc.'s
capability to be awarded contracts. All such forward-looking
statements are current only as of the date on which such statements
were made. Hard to Treat Diseases, Inc. does not undertake any
obligation to publicly update any forward-looking statement to
reflect events or circumstances after the date on which any such
statement is made or to reflect the occurrence of unanticipated
events.
CONTACT: For any investor relations matters, please contact
www.minamargroup.net/helpdesk; Investor Relations Department
Inquiry, www.minamargroup.net (IR); For (M&A) and Corporate
Matters, www.minamargroup.com
SOURCE Hard to Treat Diseases